Detailed Narrative
US FDA Approval and Market Expansion
Aarti Drugs announced the successful US FDA approval for its API manufacturing facility at plot number E22, Tarapur, Maharashtra. This approval enables the company to export API products such as Ciprofloxacin HCL, Zolpidem Tartrate, and Celecoxib to the US market. Management estimates this plant has a potential to generate INR70-80 crores in annual revenue with EBITDA margins exceeding 30%, significantly higher than current company averages. While initial sales to the US market are expected to flow in FY27 due to gestation periods, European markets are anticipated to open faster.
Green Energy and ESG Initiatives
The company is advancing its commitment to green energy by acquiring a 26.25% equity stake in a solar power plant Special Purpose Vehicle (SPV). This initiative aims to provide approximately 8.9 million renewable units per annum, leading to an estimated annual saving of INR3.6 crores for its Gujarat plant by H1 FY26. This project is also expected to reduce carbon dioxide emissions by around 1,000 tons. Furthermore, Aarti Drugs achieved an EcoVadis assessment score of 69, placing it in the 89th percentile globally and securing a silver medal for its overall ESG performance.
Q3 FY25 Financial Performance and Margin Outlook
For Q3 FY25, Aarti Drugs reported a revenue of INR568 crores, a 6% decline from INR607 crores in Q3 FY24, primarily due to reduced market prices and weaker demand in the Formulation and Antibiotics API segments. Despite this, gross profit increased by 7% to INR207 crores. The Formulation segment contributed INR48.6 crores to revenue, with 47% from exports. Management is optimistic about achieving double-digit revenue growth in the coming years and targets an EBITDA margin of 13-14% for FY26, with a long-term goal of 15% EBITDA margins within two years, driven by backward integration and capacity utilization.
Greenfield Projects and Capacity Expansion
The greenfield project at Sayakha, Gujarat, focused on Specialty Chemicals and backward integration, is slated to begin trial production in February 2025 (Q4 FY25), with operating leverage expected from the subsequent quarter (Q1 FY26). The Tarapur greenfield project is ramping up production to over 500 tons per month by March 2025, aiming for a total capacity of 1,600 metric tons per month by the end of FY26. The company incurred INR136 crores in capex during 9M FY25 and anticipates a total capex of around INR200 crores for the full FY25, funded through internal accruals and term loans.
Formulation Segment Growth and Product Pipeline
The Formulation segment is expected to see flattish growth in the immediate next quarter but strong growth in the next financial year, particularly in exports. A brownfield expansion in the Formulation segment has added 30% additional capacities, with revenues from these additions expected to kick in from Q1 FY26. The company plans to launch 5 oncology products in the US and Europe soon, and 6-7 new antidiabetic products (including DPP-4 inhibitors and SGLT2s) over the next 1.5 years, broadening its market reach and product diversity.
Operational Challenges and Chlorosulfonation Line Adjustment
Management disclosed that a newer chlorosulfonation line, initially planned for 300-400 tons per month with a continuous process, faced quality issues with raw materials, leading to lower derivative rates and market unacceptability. Consequently, the company rolled back to the old batch process, with current operational capacity at 100 tons per month. All losses from the quality issues have been curtailed, and steps are being taken to increase capacity back to the original planned levels using the older, reliable process within 3-4 months.